Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Celecoxib Before Surgery for Endometrial Cancer
NCT03896113Phase 2Unknown
- Start
- Nov 2019
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of celecoxib oral solution in endometrial cancer (EC). Primary endpoints: Reduction of tumoural cells expression IDO at 15 days and Modification of tumoural T Cells infiltration at 15 days. Status: unknown.
02
Drugs
celecoxib oral solution
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT03896113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03896113.